260 results
424B5
MSD Netherlands Capital B.V.
15 May 24
Prospectus supplement for primary offering
4:07pm
promising in development but fail to reach the market because of efficacy or safety concerns, the inability to obtain necessary regulatory approvals … and the enforcement thereof affecting our business.
Efficacy or safety concerns with respect to marketed products, whether or not scientifically justified
8-K
EX-99.1
MRK
Merck & Co Inc
25 Apr 24
Merck Announces First-Quarter 2024 Financial Results
6:41am
Phase 2/3 trial evaluating the efficacy and safety of investigational raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer … , as well as plans to conduct clinical trials in both females and males (16-26 years old) to evaluate the efficacy and safety of a single-dose regimen
8-K
EX-99.1
tcsd h21m0agfh8
26 Oct 23
Merck Announces Third-Quarter 2023 Financial Results
6:38am
8-K
EX-99.1
gu95c4 eo91e
1 Aug 23
Merck Announces Second-Quarter 2023 Financial Results
6:46am
424B5
zcahf
10 May 23
Prospectus supplement for primary offering
4:27pm
424B5
r06r0vf04 i91xw
8 May 23
Prospectus supplement for primary offering
8:17am
8-K
EX-99.1
i9m3uy pz5
27 Oct 22
Merck Announces Third-Quarter 2022 Financial Results
6:38am
8-K
EX-99.1
dz4h7uk hg
28 Apr 22
Merck Announces First-Quarter 2022 Financial Results
6:35am